Marshall Wace
HCAT icon

Marshall Wace’s Health Catalyst HCAT Stock Holding History

Marshall Wace’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,969
Closed -$155K – 3127
2022
Q3 		$155K Sell
15,969
-106,259
-87% -$1.41M ﹤0.01% 3133
2022
Q2 		$1.77M Buy
+122,228
New +$2.08M ﹤0.01% 2081
2021
Q4 		– Sell
-73,321
Closed -$3.67M – 4026
2021
Q3 		$3.67M Buy
+73,321
New +$4M 0.02% 1145
2021
Q2 		– Sell
-544,171
Closed -$25.5M – 2806
2021
Q1 		$25.5M Sell
544,171
-386,015
-41% -$18.7M 0.12% 179
2020
Q4 		$40.5M Buy
930,186
+70,456
+8% +$2.6M 0.22% 97
2020
Q3 		$31.5M Sell
859,730
-54,023
-6% -$1.83M 0.2% 115
2020
Q2 		$26.7M Sell
913,753
-106,605
-10% -$2.95M 0.19% 122
2020
Q1 		$26.7M Buy
+1,020,358
New +$31.2M 0.27% 81

Other funds holding HCAT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DG
Daventry Group New York $133M AUM 32.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's HCAT Position: Q4 2022 in Review

Marshall Wace sold out of Health Catalyst (HCAT) in Q4 2022, closing a stake of 15,969 shares — an estimated $155K sold.

Marshall Wace first reported a position in HCAT in Q1 2020 and held it in 8 quarters. The position peaked at $40.5M in Q4 2020. 166 funds tracked by Wall St. Rank hold HCAT as of Q4 2022.

  • Marshall Wace reported no remaining Health Catalyst position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 15,969 Health Catalyst shares in Q4 2022, an estimated $155K.
  • Marshall Wace first reported a position in Health Catalyst in Q1 2020 and held it in 8 quarters.
  • Marshall Wace's Health Catalyst position peaked at $40.5M in Q4 2020.
  • 166 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.